Cantor Fitzgerald Predicts AVITA Medical FY2026 Earnings

AVITA Medical, Inc. (NASDAQ:RCEL - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of AVITA Medical in a report issued on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn expects that the company will earn ($0.23) per share for the year. The consensus estimate for AVITA Medical's current full-year earnings is ($0.95) per share.

Separately, D. Boral Capital restated a "buy" rating and set a $19.00 price objective on shares of AVITA Medical in a research report on Friday, June 6th.

AVITA Medical Price Performance

RCEL traded down $0.14 during trading on Wednesday, reaching $5.92. 55,762 shares of the company traded hands, compared to its average volume of 183,008. The company has a market cap of $156.50 million, a P/E ratio of -2.48 and a beta of 1.55. The firm has a fifty day simple moving average of $7.78 and a 200 day simple moving average of $9.42. AVITA Medical has a 12-month low of $5.46 and a 12-month high of $14.16. The company has a debt-to-equity ratio of 9.39, a quick ratio of 2.47 and a current ratio of 2.83.

AVITA Medical (NASDAQ:RCEL - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.14). The firm had revenue of $18.51 million during the quarter, compared to analysts' expectations of $33.15 million. AVITA Medical had a negative return on equity of 337.91% and a negative net margin of 96.26%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in AVITA Medical by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 1,423,439 shares of the company's stock valued at $18,220,000 after acquiring an additional 5,767 shares during the period. Geode Capital Management LLC increased its stake in AVITA Medical by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 597,595 shares of the company's stock worth $7,650,000 after buying an additional 3,159 shares during the period. Essex Investment Management Co. LLC lifted its stake in AVITA Medical by 13.0% in the fourth quarter. Essex Investment Management Co. LLC now owns 261,171 shares of the company's stock worth $3,343,000 after acquiring an additional 30,077 shares during the last quarter. Northern Trust Corp lifted its position in shares of AVITA Medical by 5.7% during the 4th quarter. Northern Trust Corp now owns 228,720 shares of the company's stock worth $2,928,000 after buying an additional 12,253 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new position in shares of AVITA Medical in the 1st quarter valued at $799,000. Hedge funds and other institutional investors own 27.66% of the company's stock.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.